Tissue Regenix Group (LSE:TRX) Scaled Net Operating Assets : 0.76 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Tissue Regenix Group Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Tissue Regenix Group's operating assets for the quarter that ended in Dec. 2023 was £30.49 Mil. Tissue Regenix Group's operating liabilities for the quarter that ended in Dec. 2023 was £3.55 Mil. Tissue Regenix Group's Total Assets for the quarter that ended in Jun. 2023 was £35.59 Mil. Therefore, Tissue Regenix Group's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.76.

Tissue Regenix Group Scaled Net Operating Assets Historical Data

The historical data trend for Tissue Regenix Group's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tissue Regenix Group Scaled Net Operating Assets Chart

Tissue Regenix Group Annual Data

Trend

Jan14

Jan15

Jan16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.65

0.79

0.68

0.80

0.71

Tissue Regenix Group Semi-Annual Data
	Jan14	Jul14	Jan15	Jul15	Jan16	Jul16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.75	0.78	0.77	0.74	0.76

Competitive Comparison of Tissue Regenix Group's Scaled Net Operating Assets

For the Biotechnology subindustry, Tissue Regenix Group's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tissue Regenix Group's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Tissue Regenix Group's Scaled Net Operating Assets falls into.

Tissue Regenix Group Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Tissue Regenix Group's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(30.488	-	3.55)	/	37.798
=	0.71

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	34.162	-	3.674
=	30.488

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	10.972	-	6.915	-	0.507
=	3.55

Tissue Regenix Group's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2023 )
=	(Operating Assets (Q: Dec. 2023 )	-	Operating Liabilities (Q: Dec. 2023 ))	/	Total Assets (Q: Jun. 2023 )
=	(30.488	-	3.55)	/	35.591
=	0.76

where

	Operating Assets		(Q: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	34.162	-	3.674
=	30.488

	Operating Liabilities		(Q: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	10.972	-	6.915	-	0.507
=	3.55

Tissue Regenix Group Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Tissue Regenix Group's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Tissue Regenix Group (LSE:TRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tissue Regenix Group PLC (LSE:TRX) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

LSW:Germany

Address

Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY

Website

https://www.tissueregenix.com

Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.